Two Sigma Investments LP Buys 23,822 Shares of Medifast, Inc. (NYSE:MED)

Two Sigma Investments LP lifted its position in Medifast, Inc. (NYSE:MED - Free Report) by 11.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 232,069 shares of the specialty retailer's stock after purchasing an additional 23,822 shares during the quarter. Two Sigma Investments LP owned 2.12% of Medifast worth $4,089,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of MED. Wells Fargo & Company MN boosted its holdings in Medifast by 23.5% during the 4th quarter. Wells Fargo & Company MN now owns 6,459 shares of the specialty retailer's stock valued at $114,000 after acquiring an additional 1,227 shares during the period. State of Wyoming raised its position in Medifast by 286.1% during the 4th quarter. State of Wyoming now owns 11,312 shares of the specialty retailer's stock valued at $199,000 after purchasing an additional 8,382 shares during the last quarter. Nisa Investment Advisors LLC raised its position in Medifast by 2,308.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 11,442 shares of the specialty retailer's stock valued at $202,000 after purchasing an additional 10,967 shares during the last quarter. Barclays PLC raised its position in Medifast by 15.1% during the 4th quarter. Barclays PLC now owns 16,194 shares of the specialty retailer's stock valued at $285,000 after purchasing an additional 2,127 shares during the last quarter. Finally, Exchange Traded Concepts LLC raised its position in Medifast by 4.1% during the 4th quarter. Exchange Traded Concepts LLC now owns 17,106 shares of the specialty retailer's stock valued at $301,000 after purchasing an additional 674 shares during the last quarter. 95.51% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have commented on MED. DA Davidson lowered their price target on Medifast from $17.00 to $16.50 and set a "neutral" rating for the company in a research report on Wednesday, February 19th. Wall Street Zen raised Medifast from a "hold" rating to a "buy" rating in a research report on Thursday, May 1st.

Medifast Stock Up 1.1%

Shares of NYSE:MED traded up $0.16 during trading on Friday, hitting $14.10. The stock had a trading volume of 238,564 shares, compared to its average volume of 289,200. Medifast, Inc. has a 12 month low of $11.57 and a 12 month high of $26.53. The company has a market capitalization of $154.97 million, a PE ratio of 78.33 and a beta of 0.96. The firm's fifty day moving average is $13.05 and its 200 day moving average is $15.29.

Medifast (NYSE:MED - Get Free Report) last announced its earnings results on Monday, April 28th. The specialty retailer reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.04). Medifast had a return on equity of 10.64% and a net margin of 0.35%. The firm had revenue of $115.73 million during the quarter, compared to the consensus estimate of $114.85 million. Equities research analysts expect that Medifast, Inc. will post 0.51 EPS for the current fiscal year.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.